CR20150477A - Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso - Google Patents

Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso

Info

Publication number
CR20150477A
CR20150477A CR20150477A CR20150477A CR20150477A CR 20150477 A CR20150477 A CR 20150477A CR 20150477 A CR20150477 A CR 20150477A CR 20150477 A CR20150477 A CR 20150477A CR 20150477 A CR20150477 A CR 20150477A
Authority
CR
Costa Rica
Prior art keywords
methods
polypeptides
fusion proteins
composition
relates
Prior art date
Application number
CR20150477A
Other languages
English (en)
Inventor
Justin Scheer
Wenjun Ouyang
Eric Gary Stefanich
Richard Vandlen
Philip E Haas
Ganesh A Kolumam
Xiaoting Wang
Jed Ross
Bruggen Nicholas Van
Wyne P Lee
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/029652 external-priority patent/WO2014145016A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CR20150477A publication Critical patent/CR20150477A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La invención se refiere a polipéptidos de IL-22, proteínas de fusión de IL-22, composición que los comprende, métodos de fabricación y métodos de utilización de la composición para el tratamiento de enfermedades. La invención también se refiere al receptor de IL-22 asociado a reactivos y métodos de uso de los mismos.
CR20150477A 2013-03-15 2015-09-11 Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso CR20150477A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361801144P 2013-03-15 2013-03-15
US201361800148P 2013-03-15 2013-03-15
US201361800795P 2013-03-15 2013-03-15
PCT/US2014/029652 WO2014145016A2 (en) 2013-03-15 2014-03-14 Il-22 polypeptides and il-22 fc fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
CR20150477A true CR20150477A (es) 2015-10-26

Family

ID=54838123

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150477A CR20150477A (es) 2013-03-15 2015-09-11 Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso

Country Status (2)

Country Link
US (1) US20180355009A1 (es)
CR (1) CR20150477A (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165140A1 (en) * 2018-02-21 2019-08-29 Genentech, Inc. DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022542240A (ja) * 2019-07-26 2022-09-30 ジェネンテック， インコーポレイテッド ＩＬ－２２ Ｆｃ融合タンパク質による移植片対宿主病（ＧＶＨＤ）の予防又は治療のための投薬
WO2021046133A1 (en) * 2019-09-03 2021-03-11 Amgen Inc. Il-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165140A1 (en) * 2018-02-21 2019-08-29 Genentech, Inc. DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS

Also Published As

Publication number Publication date
US20180355009A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
CL2015002654A1 (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
AR107078A1 (es) Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
CL2019000261A1 (es) Polipéptidos modificados y usos de los mismos.
CR20230179A (es) PROTEÍNAS DE FUSIÓN FC HETERODIMÉRICAS IL 15/IL15Ra (Divisional 2019-0229)
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
CO2018009995A2 (es) Proteínas de unión y métodos de uso de las mismas
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
CR20170326A (es) Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
BR112016022841A2 (pt) cadeia j modificada
UY35407A (es) ?PROTEÍNAS DE FUSIÓN COMPRENDIENDO PORCIONES PDGF y VEGF DE UNIÓN Y MÉTODOS PARA SU USO?.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
ECSP13013022A (es) Agonistas de fgfr1 y sus métodos de uso
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
UY36678A (es) Anticuerpos anti-fcrn.
UY35835A (es) Anticuerpos específicos para FcRn.
PE20151925A1 (es) Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares
BR112016019390A2 (pt) proteínas de fusão uti
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
DOP2016000105A (es) Anticuerpos anti-ccl17.
CR20150477A (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
CR20190229A (es) PROTEÍNAS DE FUSIÓN FC HETERODIMÉRICAS IL15/IL15Ra